Researchers reported that whole-body diffusion-weighted MRI (WB-DWI/MRI) can predict treatment outcomes for patients with advanced ovarian cancer following neoadjuvant chemotherapy. The findings, published in the British Journal of Cancer, evaluate how imaging features after NACT correlate with subsequent clinical endpoints. WB-DWI/MRI is a whole-body functional imaging approach that helps characterize tumor cellularity and treatment response through diffusion signals—often used to assess spread and lesion-level changes. In this study, the imaging framework aims to improve risk stratification rather than relying solely on pathology after surgery. For biotech and pharma, the practical impact is measurement: more reliable imaging predictors can support trial endpoints and help teams refine selection criteria for subsequent therapies.